Transformative Precision Medicines for Patients in Need
Plexium is a next-generation targeted protein degradation (TPD) biotech company developing monovalent degraders — including Monovalent Direct Degraders and Molecular Glues — using a proprietary ultra-high throughput cell-based screening (uHTS) platform. The company's AI-integrated drug discovery approach enables rational design of protein degrader therapeutics for cancer and neurodegenerative diseases. Plexium has established partnerships with Amgen and AbbVie for TPD drug discovery collaborations and maintains a wholly-owned pipeline alongside partnered programs.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2025
Feb 2022
Jan 2021
Feb 2018
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
